Cargando…
Primary Hepatic Lymphoma: A Retrospective, Multicenter Rare Cancer Network Study
Primary hepatic lymphoma (PHL) is a rare malignancy. We aimed to assess the clinical profile, outcome and prognostic factors in PHL through the Rare Cancer Network (RCN). A retrospective analysis of 41 patients was performed. Median age was 62 years (range, 23-86 years) with a male-to-female ratio o...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
PAGEPress Publications, Pavia, Italy
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5064304/ https://www.ncbi.nlm.nih.gov/pubmed/27746888 http://dx.doi.org/10.4081/rt.2016.6502 |
_version_ | 1782460130853388288 |
---|---|
author | Ugurluer, Gamze Miller, Robert C. Li, Yexiong Thariat, Juliette Ghadjar, Pirus Schick, Ulrike Ozsahin, Mahmut |
author_facet | Ugurluer, Gamze Miller, Robert C. Li, Yexiong Thariat, Juliette Ghadjar, Pirus Schick, Ulrike Ozsahin, Mahmut |
author_sort | Ugurluer, Gamze |
collection | PubMed |
description | Primary hepatic lymphoma (PHL) is a rare malignancy. We aimed to assess the clinical profile, outcome and prognostic factors in PHL through the Rare Cancer Network (RCN). A retrospective analysis of 41 patients was performed. Median age was 62 years (range, 23-86 years) with a male-to-female ratio of 1.9:1.0. Abdominal pain or discomfort was the most common presenting symptom. Regarding B-symptoms, 19.5% of patients had fever, 17.1% weight loss, and 9.8% night sweats. The most common radiological presentation was multiple lesions. Liver function tests were elevated in 56.1% of patients. The most common histopathological diagnosis was diffuse large B-cell lymphoma (65.9%). Most of the patients received Chop-like (cyclophosphamide, doxorubicin, vincristine, and prednisone) regimens; 4 patients received radiotherapy (dose range, 30.6-40.0 Gy). Median survival was 163 months, and 5- and 10-year overall survival rates were 77 and 59%, respectively. The 5- and 10-year disease-free and lymphoma-specific survival rates were 69, 56, 87 and 70%, respectively. Multivariate analysis revealed that fever, weight loss, and normal hemoglobin level were the independent factors influencing the outcome. In this retrospective multicenter RCN study, patients with PHL had a relatively better prognosis than that reported elsewhere. Multicenter prospective studies are still warranted to establish treatment guidelines, outcome, and prognostic factors. |
format | Online Article Text |
id | pubmed-5064304 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | PAGEPress Publications, Pavia, Italy |
record_format | MEDLINE/PubMed |
spelling | pubmed-50643042016-10-14 Primary Hepatic Lymphoma: A Retrospective, Multicenter Rare Cancer Network Study Ugurluer, Gamze Miller, Robert C. Li, Yexiong Thariat, Juliette Ghadjar, Pirus Schick, Ulrike Ozsahin, Mahmut Rare Tumors Article Primary hepatic lymphoma (PHL) is a rare malignancy. We aimed to assess the clinical profile, outcome and prognostic factors in PHL through the Rare Cancer Network (RCN). A retrospective analysis of 41 patients was performed. Median age was 62 years (range, 23-86 years) with a male-to-female ratio of 1.9:1.0. Abdominal pain or discomfort was the most common presenting symptom. Regarding B-symptoms, 19.5% of patients had fever, 17.1% weight loss, and 9.8% night sweats. The most common radiological presentation was multiple lesions. Liver function tests were elevated in 56.1% of patients. The most common histopathological diagnosis was diffuse large B-cell lymphoma (65.9%). Most of the patients received Chop-like (cyclophosphamide, doxorubicin, vincristine, and prednisone) regimens; 4 patients received radiotherapy (dose range, 30.6-40.0 Gy). Median survival was 163 months, and 5- and 10-year overall survival rates were 77 and 59%, respectively. The 5- and 10-year disease-free and lymphoma-specific survival rates were 69, 56, 87 and 70%, respectively. Multivariate analysis revealed that fever, weight loss, and normal hemoglobin level were the independent factors influencing the outcome. In this retrospective multicenter RCN study, patients with PHL had a relatively better prognosis than that reported elsewhere. Multicenter prospective studies are still warranted to establish treatment guidelines, outcome, and prognostic factors. PAGEPress Publications, Pavia, Italy 2016-10-06 /pmc/articles/PMC5064304/ /pubmed/27746888 http://dx.doi.org/10.4081/rt.2016.6502 Text en ©Copyright G. Ugurluer et al. http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Article Ugurluer, Gamze Miller, Robert C. Li, Yexiong Thariat, Juliette Ghadjar, Pirus Schick, Ulrike Ozsahin, Mahmut Primary Hepatic Lymphoma: A Retrospective, Multicenter Rare Cancer Network Study |
title | Primary Hepatic Lymphoma: A Retrospective, Multicenter Rare Cancer Network Study |
title_full | Primary Hepatic Lymphoma: A Retrospective, Multicenter Rare Cancer Network Study |
title_fullStr | Primary Hepatic Lymphoma: A Retrospective, Multicenter Rare Cancer Network Study |
title_full_unstemmed | Primary Hepatic Lymphoma: A Retrospective, Multicenter Rare Cancer Network Study |
title_short | Primary Hepatic Lymphoma: A Retrospective, Multicenter Rare Cancer Network Study |
title_sort | primary hepatic lymphoma: a retrospective, multicenter rare cancer network study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5064304/ https://www.ncbi.nlm.nih.gov/pubmed/27746888 http://dx.doi.org/10.4081/rt.2016.6502 |
work_keys_str_mv | AT ugurluergamze primaryhepaticlymphomaaretrospectivemulticenterrarecancernetworkstudy AT millerrobertc primaryhepaticlymphomaaretrospectivemulticenterrarecancernetworkstudy AT liyexiong primaryhepaticlymphomaaretrospectivemulticenterrarecancernetworkstudy AT thariatjuliette primaryhepaticlymphomaaretrospectivemulticenterrarecancernetworkstudy AT ghadjarpirus primaryhepaticlymphomaaretrospectivemulticenterrarecancernetworkstudy AT schickulrike primaryhepaticlymphomaaretrospectivemulticenterrarecancernetworkstudy AT ozsahinmahmut primaryhepaticlymphomaaretrospectivemulticenterrarecancernetworkstudy |